About this trial
Individuals with schizophrenia often experience persistent auditory hallucinations despite treatment with antipsychotic medications. Research suggests that abnormal communication between the striatum and the auditory cortex contributes to hallucinations. This first-in-human, proof-of-concept Phase 1 study will evaluate the safety, feasibility, and preliminary effects of repeated-session low-intensity focused ultrasound (LIFU), a non-invasive neuromodulation technique targeting the striatum. The study will examine whether LIFU can safely modulate brain circuits involved in hallucinations, reduce abnormal communication between the striatum and auditory cortex, and improve auditory hallucination symptoms.
Eligibility criteria
Qualifiers
18-64 years of age, inclusive of all gender identities
Current DSM-5 diagnosis of schizophrenia
Persistent clinically-significant auditory hallucinations
No contraindications for MRI, confirmed via standard safety screening procedures
Disqualifiers
None
Trial design
Treatments tested in this trial
- LIFU
Treatment groups
Sponsors and collaborators
University of California, San Francisco
Lead sponsor
Attune Neurosciences Inc
Collaborator